Within the long and patient effort to understand how the body keeps its own cells in check, researchers at Adelaide University have found a small stretch of regulatory DNA that helps restrain the growth of the most common form of breast cancer. The discovery, made so far only in laboratory cultures, shifts attention away from a gene that had seemed the likely culprit and toward a tiny switch within it. It offers scientists a clearer map of how future treatments for hormone-driven disease might one day be shaped, though the path from the bench to the bedside remains long.
DNA 'Switch' Found to Help Slow the Growth of the Most Common Breast Cancer
A small DNA 'switch' sitting inside the gene helps restrain cancer cell growth
Mark
Why does a tiny piece of DNA matter this much?
Mimi
Because researchers already knew the androgen receptor could suppress ER+ breast cancer, but not exactly how. This region, HRRINT3, looks like part of the answer.
Mark
And it wasn't where they expected to find it?
Mimi
No. They had focused on the gene ZBTB16, since higher levels were linked to better survival. But changing the gene's levels didn't affect growth suppression. The switch sitting inside it did.
Luke
Worth pausing on that survival link, though. It came from earlier work, and this study shows the gene itself isn't driving the suppression. What explains the survival association isn't addressed in the reporting.
Mark
How did they show the enhancer matters?
Mimi
They used CRISPR to remove a small section of it. The androgen receptor then did a poorer job of suppressing cell growth, its signalling was disrupted, and cell-division genes became more active.
Luke
All of that is in cell models. Nothing here involves patients.
Mark
Does it reach beyond ER+ breast cancer?
Mimi
The team reported effects in other androgen receptor-positive breast and prostate cancer cell models, so the region may have a wider role.
Luke
"May" is carrying weight there. It's a possibility the researchers raise, not an established finding. And we don't know how many models or how strong the effects were.
Mark
So what's the realistic takeaway?
Mimi
Better understanding of how androgen receptor-activating treatments work, which could eventually help pick patients who'd benefit, especially those no longer responding to hormone therapy.
Luke
Eventually is the operative word. The source says plainly this doesn't establish a new treatment.
Il Polso
- A common and stubborn breast cancer, driven by oestrogen, grows hardest to treat once patients stop responding to hormone therapy.
- The team's first suspect, the gene ZBTB16, proved innocent when its levels were altered, unsettling their earlier understanding.
- Using CRISPR gene editing, scientists cut a small section of an enhancer called HRRINT3 and watched the androgen receptor lose its power to slow tumour cells.
- The findings, published in npj Breast Cancer, remain laboratory-bound, leaving clinical relevance for resistant patients unproven and the next steps still to be charted.
Within the long and patient effort to understand how the body keeps its own cells in check, researchers at Adelaide University have found a small stretch of regulatory DNA that helps restrain the growth of the most common form of breast cancer. The discovery, made so far only in laboratory cultures, shifts attention away from a gene that had seemed the likely culprit and toward a tiny switch within it. It offers scientists a clearer map of how future treatments for hormone-driven disease might one day be shaped, though the path from the bench to the bedside remains long.
Researchers at Adelaide University, working with colleagues at the South Australian immunoGENomics Cancer Institute, SAHMRI and the University of Bordeaux, have uncovered a small piece of regulatory DNA that helps hold back a common form of breast cancer. The disease in question, oestrogen receptor-positive breast cancer, accounts for as many as 80 per cent of cases and is fed by oestrogen. It becomes especially difficult to treat when patients no longer respond to hormone therapies.
Earlier work had hinted that the androgen receptor, a hormone receptor, can act as a tumour suppressor in these cancers, and treatments that activate it are already being explored. The mechanisms, however, remained unclear. The team's first suspect was the gene ZBTB16, since higher levels of it had been linked to better survival. Yet changing its levels in cancer cells left the receptor's growth-suppressing power untouched.
The real action lay within the gene itself, in a small enhancer called HRRINT3. Dr Amy Dwyer described the surprise: a small DNA switch, not the gene as a whole, was doing the work. When the researchers used CRISPR to remove part of this region, the receptor lost much of its ability to restrain cell growth, signalling was disrupted, and genes linked to cell division grew more active. The effect also appeared in other androgen receptor-positive breast and prostate cancer models, hinting at a wider regulatory network.
The work stays firmly in the laboratory for now. It does not yield a new treatment, but it may help clinicians one day identify which patients could benefit from androgen-targeting approaches, particularly those whose cancers have stopped answering to existing therapies.
Researchers at Adelaide University have found a small stretch of regulatory DNA that helps the body hold back the growth of the most common form of breast cancer. The finding, from laboratory work, gives scientists a clearer view of how future treatments might be built.
The cancer in question is oestrogen receptor-positive breast cancer, or ER+, which makes up as many as 80 per cent of breast cancer cases. It is fuelled by the hormone oestrogen. It becomes hard to treat when patients stop responding to hormone therapies.
The new work builds on earlier research suggesting that another hormone receptor, the androgen receptor, can act as a tumour suppressor in ER+ breast cancer. Activating that receptor has been explored as a treatment approach, but the precise mechanisms behind its effects have not been fully understood. The team, drawn from Adelaide University's School of Medicine, the South Australian immunoGENomics Cancer Institute (SAiGENCI) and the South Australian Health and Medical Research Institute (SAHMRI), set out to examine that gap.
Their starting point was a gene called ZBTB16. In earlier work, the researchers had found that higher levels of it were linked to better survival among patients with ER+ breast cancer. It seemed a natural suspect. But when they changed ZBTB16 levels in breast cancer cells, the androgen receptor's ability to suppress cell growth was unaffected.
What they found instead was a small regulatory region inside the gene, called HRRINT3, which acts as an enhancer and helps control gene activity. Dr Amy Dwyer, from the School of Medicine, said the result upended the team's earlier thinking. "The surprising finding was that ZBTB16 itself was not responsible for the growth-suppressing effect," she said. "Instead, we found that a small DNA 'switch' sitting inside the gene helps the androgen receptor to restrain cancer cell growth."
The researchers found that when androgens, hormones present in both women and men, activate the androgen receptor, it binds to this enhancer. To test what the region does, they used CRISPR gene-editing technology to remove a small section of HRRINT3. Dr Zeyad Nassar, a cancer researcher with SAiGENCI and SAHMRI, said that removing it reduced the receptor's capacity to suppress breast cancer cell growth. The team also saw disrupted androgen receptor signalling and higher activity in genes tied to cell division.
Those results suggest the enhancer may be one part of a wider regulatory network controlling cancer cell growth, rather than working only through ZBTB16. The team also reported effects in other androgen receptor-positive breast and prostate cancer cell models, which raises the possibility that the region plays a broader role in regulating tumour growth. The study was published in npj Breast Cancer and carried out with researchers at the University of Bordeaux in France.
Treatments designed to activate the androgen receptor are already under investigation for advanced ER+ breast cancer. Understanding the molecular processes involved could help researchers identify which patients might benefit, particularly those whose disease no longer responds to existing hormone therapies.
The limits are clear, though. The findings are based on laboratory research and do not establish a new treatment. Further investigation will be needed to determine how the discovery could translate into clinical care.
Citazioni salienti
The surprising finding was that ZBTB16 itself was not responsible for the growth-suppressing effect.— Dr Amy Dwyer, Adelaide University School of Medicine
Removing the DNA region reduced the androgen receptor's ability to suppress breast cancer cell growth (paraphrased).— Dr Zeyad Nassar, SAiGENCI and SAHMRI
Vuoi la storia completa?
Leggi l'originale su The Indian Sun ↗
Science & Space